The "New" Antipsychotic That's Basically a Remix of an Old One
The FDA just approved Vanda's Bysanti for schizophrenia and bipolar I, but here's the twist: your body converts it right back into the company's older drug. Is this clever lifecycle strategy or a $20 billion market remix that could save a struggling company?
A Familiar Molecule in a Brand-New Suit
Imagine a musician releasing an album of remixed tracks and calling it an entirely new record. That's essentially what Vanda Pharmaceuticals just pulled off with the FDA.
On February 20, 2026, the agency approved Bysanti (milsaperidone) for treating schizophrenia and acute manic or mixed episodes in bipolar I disorder. It's a brand-new chemical entity. It's got a shiny new name and fresh patent protection stretching all the way to 2044. And once you swallow it, your body converts a portion of it right back into iloperidone, the active ingredient in Vanda's older drug Fanapt.
That's not a bug. It's the entire business model.
How One Drug Becomes Two (Sort Of)
Milsaperidone and iloperidone exist in a kind of pharmacological buddy-cop relationship. When you take Bysanti, the two molecules rapidly swap back and forth in your bloodstream, maintaining a steady-state ratio of about 60% milsaperidone and 40% iloperidone. Together, they block the same trio of receptors that most atypical antipsychotics target: dopamine D2, serotonin 5-HT2A, and alpha-1 adrenergic receptors.
What makes Bysanti interesting (at least on paper) is its receptor binding profile. It's been described as an "ultra-strong" 5-HT2A antagonist. Translation: it latches onto serotonin receptors with unusual intensity, which could mean fewer movement-related side effects (the jittery, involuntary twitches called extrapyramidal symptoms) compared to older drugs. It also binds alpha-adrenergic receptors more aggressively than it binds dopamine or serotonin, a trait Vanda believes could help with agitation and hostility.
But the honest truth? The underlying mechanism is not novel. It's the same dopamine-plus-serotonin playbook that atypical antipsychotics have been running since the 1990s.
The Evidence (Borrowed, Not Built)
Because Bysanti is bioequivalent to iloperidone across the therapeutic dosing range, the FDA let Vanda lean heavily on Fanapt's existing clinical data.
For schizophrenia, two pivotal placebo-controlled trials told the story. In one six-week study of 706 patients, flexible doses of iloperidone (12–16 mg/day and 20–24 mg/day) beat placebo on the PANSS total score, which measures the severity of psychotic symptoms. A second four-week study of 604 patients confirmed the result at a fixed 24 mg/day dose. A third trial, called REPRIEVE, showed that patients who stayed on the drug relapsed significantly later than those switched to placebo.
More from this issue
View full issue →
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
